Melflufen is a novel peptide–drug conjugate that rapidly delivers a cytotoxic payload into
tumor cells. It has emerged as a potential new multiple myeloma treatment, particularly for …

Monoclonal Gammopathies of Renal Significance (MGRS) are a rather heterogeneous
group of renal disorders caused by a circulating monoclonal (MC) immunoglobulin (Ig) …

Given the lack of large cohort with comprehensive clinical and cytogenetic assessment,
knowledge about IgD myeloma is obtained mostly from a limited sample size [7]. Therefore …

Objective IgD multiple myeloma (MM) is a rare type of MM, accounting for about 1%–2% of
all MMs. IgD MM always causes kidney damage and even leads to renal failure, which is the …

Immunoglobulin D (IgD) multiple myeloma (MM) is a rare subtype of MM that carries a worse
prognosis than non-IgD subtypes. Compared with non-IgD subtypes, IgD MM is associated …

Immunoglobulin D (IgD) myeloma represents an uncommon subtype of multiple myeloma
(MM), accounting for 1–2% of cases. Subjects affected by IgD MM have been demonstrated …

IgD multiple myeloma is uncommon. Patients generally present at a younger age and have
shorter progression free and overall survivals (OSs). Its rarity has inhibited development of a …

Background IgD Multiple Myeloma is a rare form of plasma cell dyscrasia and accounts for
approximately 1-2% of all cases of Multiple Myeloma. It mainly affects young, male subjects; …

Abstract Background The Collaboration to Collect Autologous Transplant Outcomes in
Lymphoma and Myeloma (CALM) study has provided an opportunity to evaluate the real …

MM (multiple myeloma) accounts for about 10% of hematological malignancies and 1% of
cancer. IgD myeloma is a rare type of MM. It was reported that IgD type accounts for about …